Compare SER & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | MYO |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 44.8M |
| IPO Year | 2024 | 2017 |
| Metric | SER | MYO |
|---|---|---|
| Price | $2.81 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $15.00 | $7.67 |
| AVG Volume (30 Days) | 40.9K | ★ 517.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $130,000.00 | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 132.14 | ★ 40814.79 |
| 52 Week Low | $1.22 | $0.61 |
| 52 Week High | $7.92 | $1.59 |
| Indicator | SER | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 74.64 | 74.71 |
| Support Level | $1.74 | $0.69 |
| Resistance Level | $2.99 | N/A |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 90.91 | 97.45 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.